Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and RIPC for Organ Protection in TKA
NCT05661227Unknown
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dexmedetomidine in reperfusion injury (IRI) (4 arms), sponsored by The Third Hospital of Hebei Medical University. Primary endpoints: Superoxide Dismutase, Malondialdehyde and 4 more. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT05661227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661227.